ATE266019T1 - Heteroaromatische carboxamid-derivate und ihre verwendung als hemmer des enzyms ikk-2 - Google Patents

Heteroaromatische carboxamid-derivate und ihre verwendung als hemmer des enzyms ikk-2

Info

Publication number
ATE266019T1
ATE266019T1 AT01902951T AT01902951T ATE266019T1 AT E266019 T1 ATE266019 T1 AT E266019T1 AT 01902951 T AT01902951 T AT 01902951T AT 01902951 T AT01902951 T AT 01902951T AT E266019 T1 ATE266019 T1 AT E266019T1
Authority
AT
Austria
Prior art keywords
inhibitors
carboxamide derivatives
heteroaromatic carboxamide
ikk
enzyme
Prior art date
Application number
AT01902951T
Other languages
English (en)
Inventor
Andrew Baxter
Stephen Brough
Alan Faull
Craig Johnstone
Thomas Mcinally
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE266019T1 publication Critical patent/ATE266019T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40Thiophene-2-carboxylic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01902951T 2000-02-12 2001-02-07 Heteroaromatische carboxamid-derivate und ihre verwendung als hemmer des enzyms ikk-2 ATE266019T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0003154.2A GB0003154D0 (en) 2000-02-12 2000-02-12 Novel compounds
PCT/SE2001/000248 WO2001058890A1 (en) 2000-02-12 2001-02-07 Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2

Publications (1)

Publication Number Publication Date
ATE266019T1 true ATE266019T1 (de) 2004-05-15

Family

ID=9885396

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01902951T ATE266019T1 (de) 2000-02-12 2001-02-07 Heteroaromatische carboxamid-derivate und ihre verwendung als hemmer des enzyms ikk-2

Country Status (21)

Country Link
US (2) US7358376B2 (de)
EP (1) EP1261600B1 (de)
JP (1) JP4812999B2 (de)
KR (1) KR100738165B1 (de)
CN (1) CN1243747C (de)
AT (1) ATE266019T1 (de)
AU (1) AU781047B2 (de)
BR (1) BR0108143A (de)
CA (1) CA2396824C (de)
DE (1) DE60103132T2 (de)
DK (1) DK1261600T3 (de)
ES (1) ES2218376T3 (de)
GB (1) GB0003154D0 (de)
IL (2) IL150482A0 (de)
MX (1) MXPA02007734A (de)
NO (1) NO327741B1 (de)
NZ (1) NZ519947A (de)
PT (1) PT1261600E (de)
TR (1) TR200401962T4 (de)
WO (1) WO2001058890A1 (de)
ZA (1) ZA200205300B (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869956B2 (en) 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
AU2002211663A1 (en) * 2000-10-12 2002-04-22 Smith Kline Beecham Corporation Nf-$g(k)b inhibitors
CA2427284A1 (en) 2000-10-26 2002-05-30 Tularik Inc. Antiinflammation agents
JP2004529088A (ja) * 2001-02-01 2004-09-24 ブリストル−マイヤーズ スクイブ カンパニー IkBキナーゼ(IKK)のインヒビターを用いる炎症性および免疫疾患の処置法
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
CZ20033368A3 (en) * 2001-06-11 2004-04-14 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US6956052B2 (en) 2001-09-19 2005-10-18 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
WO2003027093A1 (en) * 2001-09-21 2003-04-03 Smithkline Beecham Corporation Chemical compounds
WO2003072541A2 (en) 2001-09-27 2003-09-04 Smithkline Beecham Corporation Chemical compounds
WO2003029242A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation NF-λB INHIBITORS
WO2003028731A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003037886A2 (en) * 2001-10-30 2003-05-08 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
AR037641A1 (es) 2001-12-05 2004-11-17 Tularik Inc Moduladores de inflamacion
US6974870B2 (en) 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
JP4364120B2 (ja) * 2002-06-06 2009-11-11 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換3−アミノ−チエノ[2,3−b]ピリジン−2−カルボン酸アミド化合物、その製造方法及び使用
WO2003104218A1 (en) * 2002-06-06 2003-12-18 Smithkline Beecham Corporation Nf-:b inhibitors
US7179836B2 (en) 2002-09-20 2007-02-20 Smithkline Beecham Corporation Chemical compounds
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
US20060116419A1 (en) * 2002-12-06 2006-06-01 Callahan James F Nf-kb inhibitors
US7402608B2 (en) * 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
BRPI0413585A (pt) 2003-08-15 2006-10-17 Astrazeneca Ab composto ou sal farmaceuticamente aceitável ou um precursor hidrolisável in vivo deste, uso de um composto ou um sal deste farmaceuticamente aceitável, métodos para o tratamento de cáncer, e de infecções associadas com cáncer, composição farmacêutica, e, processo para preparação e uso de um composto ou um sal farmacêuticamente aceitável ou um precursor hidrolisável in vivo
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
EP1678164B1 (de) * 2003-10-14 2007-04-11 Pharmacia Corporation Substituierte pyrazinonverbindungen zur behandlung von entzündungen
WO2005037797A1 (en) * 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
DE602004031777D1 (en) * 2004-01-05 2011-04-21 Astrazeneca Ab Thiophenderivate als chk-1-inhibitoren
MXPA06011799A (es) * 2004-04-12 2006-12-15 Sankyo Co Derivados de tienopiridina.
WO2005105777A1 (en) * 2004-05-05 2005-11-10 Pharmacia & Upjohn Company Llc Substituted thiophene amide compounds for the treatment of inflammation
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
WO2006036031A1 (ja) * 2004-09-30 2006-04-06 Takeda Pharmaceutical Company Limited 縮合フラン誘導体およびその用途
EP1876179B1 (de) 2005-04-28 2015-03-25 Takeda Pharmaceutical Company Limited Thienopyrimidonverbindungen
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
EA014083B1 (ru) 2005-06-30 2010-08-30 Смитклайн Бичам Корпорейшн Новые производные индолкарбоксамида, содержащая их фармацевтическая композиция и способ лечения
WO2007146602A1 (en) 2006-06-06 2007-12-21 Boehringer Ingelheim International Gmbh Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
CN102250074A (zh) * 2006-11-15 2011-11-23 沃泰克斯药物(加拿大)股份有限公司 用于治疗或预防黄病毒属感染的噻吩类似物
ES2397292T3 (es) * 2007-01-15 2013-03-06 Santen Pharmaceutical Co., Ltd Nuevo derivado de indol que tiene actividad inhibidora de cinasa I B
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
EP2278999B1 (de) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Ohrbehandlungsformulierungen zur behandlung von ohrenerkrankungen und -leiden
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
JP2010043070A (ja) * 2008-07-14 2010-02-25 Santen Pharmaceut Co Ltd カルバモイル基、ウレイド基及び置換オキシ基を有する新規インドール誘導体
CN102131774A (zh) * 2008-08-25 2011-07-20 参天制药株式会社 含有脲基、氨基羰基及可以具有取代基的二环式基团作为取代基的新型吡咯衍生物
WO2010024226A1 (ja) * 2008-08-25 2010-03-04 参天製薬株式会社 ウレイド基、アミノカルボニル基及び置換フェニル基を置換基として有するピロール誘導体を有効成分として含有する骨・関節疾患の予防又は治療剤
MY150568A (en) * 2008-11-14 2014-01-30 Du Pont Method for preparing a non-hydratable crystal form
EP2406249A1 (de) 2009-03-10 2012-01-18 Glaxo Group Limited Indolderivate als ikk2-inhibitoren
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2012046793A1 (ja) * 2010-10-07 2012-04-12 参天製薬株式会社 ウレイド基とアミノカルボニル基を置換基として有するチオフェン誘導体を有効成分として含有する新規jak3阻害剤
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
EP2520292A1 (de) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Verwendung von Spirangienen zur Behandlung oder Prävention von IL-8- oder IL-6-vermittelten Erkrankungen
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
DK2634185T3 (en) 2012-03-02 2016-03-21 Sareum Ltd Tyk2 kinase inhibitors
AU2017290256A1 (en) 2016-06-29 2019-01-17 Otonomy, Inc. Triglyceride otic formulations and uses thereof
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
EP4234536A3 (de) * 2017-05-05 2023-10-25 Hepanova, Inc. Aminoaryl-benzamid-verbindungen und verfahren zur verwendung davon
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468012A (en) 1973-08-09 1977-03-23 Beecham Group Ltd 2-amino-3-carboxy-thiophene derivatives
DE3529247A1 (de) * 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
US5258357A (en) * 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5571810A (en) * 1990-06-11 1996-11-05 Fujisawa Pharmaceutical Co., Ltd. Thiophene derivatives
WO1998002430A1 (en) * 1996-07-11 1998-01-22 Pfizer Pharmaceuticals Inc. Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
PT853083E (pt) * 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
US6037340A (en) 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
WO1999046244A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
HN2000000051A (es) 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
US20040024047A1 (en) * 2001-10-12 2004-02-05 Callahan James F. Nf-kb inhibitors
AU2002211663A1 (en) * 2000-10-12 2002-04-22 Smith Kline Beecham Corporation Nf-$g(k)b inhibitors
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
WO2003029242A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation NF-λB INHIBITORS
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
NO20023786D0 (no) 2002-08-09
CN1243747C (zh) 2006-03-01
WO2001058890A1 (en) 2001-08-16
US20090181962A1 (en) 2009-07-16
CA2396824A1 (en) 2001-08-16
JP4812999B2 (ja) 2011-11-09
DK1261600T3 (da) 2004-08-16
AU3070501A (en) 2001-08-20
NZ519947A (en) 2004-05-28
US20020107252A1 (en) 2002-08-08
EP1261600A1 (de) 2002-12-04
US7358376B2 (en) 2008-04-15
NO20023786L (no) 2002-09-23
CA2396824C (en) 2010-11-16
CN1425012A (zh) 2003-06-18
TR200401962T4 (tr) 2004-09-21
KR100738165B1 (ko) 2007-07-10
DE60103132T2 (de) 2005-05-12
GB0003154D0 (en) 2000-04-05
KR20030005183A (ko) 2003-01-17
IL150482A (en) 2006-08-01
AU781047B2 (en) 2005-05-05
ZA200205300B (en) 2003-10-02
ES2218376T3 (es) 2004-11-16
NO327741B1 (no) 2009-09-14
JP2003522766A (ja) 2003-07-29
PT1261600E (pt) 2004-08-31
BR0108143A (pt) 2003-01-21
MXPA02007734A (es) 2002-10-11
EP1261600B1 (de) 2004-05-06
IL150482A0 (en) 2002-12-01
DE60103132D1 (de) 2004-06-09

Similar Documents

Publication Publication Date Title
DE60103132D1 (de) Heteroaromatische carboxamid-derivate und ihre verwendung als hemmer des enzyms ikk-2
CY1111543T1 (el) Νεες ενωσεις
CY1107817T1 (el) Καρβοξαμιδια θειοφαινιου ως αναστολεις του ενζυμου ικκ-2
MXPA04000755A (es) Nuevos compuestos.
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
DE50306845D1 (de) Disubstituierte thiazolylcarboxanilide und ihre verwendung als mikrobizide
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MXPA03008754A (es) Derivados de piridina fundidos para utilizarse como agonistas receptores vaniloide para tratar dolor.
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
DE50202504D1 (de) Neue 4-aminofuropyrimidine und ihre verwendung
DE602004005016D1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
MXPA05010875A (es) Derivados de piperazina como inhibidores de renina.
SE0300092D0 (sv) Novel compounds
WO2007047646A3 (en) Substituted dihydro-isoindolones useful in treating kinase disorders
MY134026A (en) ?-carboline derivatives and its pharmaceutical use against depression and anxiety
MXPA04004981A (es) Derivados de piperazina para uso como antagonistas del receptor ccr-3 en tratamiento de asma.
TW200628153A (en) Novel compounds
ATE373636T1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
MXPA03003466A (es) Derivados de piranosido.
TR199902097A2 (xx) Mikrobial transformasyon.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1261600

Country of ref document: EP